

TRANSMITTAL LETTER
(General - Patent Pending)

Docket No.
DI-5373 CON

In Re Application No. Naggi et al.

Serial No.
09/882,187

Filing Date
June 15, 2001

Examiner
J. Young

Group Art Unit
1623

Title: PERITONEAL DIALYSIS SOLUTION CONTAINING MODIFIED ICODEXTRINS

RECEIVED

AUG 06 2003

TECH CENTER 1600/2900

TO THE COMMISSIONER FOR PATENTS:

Transmitted herewith is:

Transmittal of Information Disclosure Statement (duplicate); Supplemental Information Disclosure Statement (2 pgs.); PTO Form 1449; Six references; check in the amount of \$180.00; and return receipt postcard.

in the above identified application.

No additional fee is required.

A check in the amount of _____ is attached.

The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.

Charge the amount of _____

Credit any overpayment.


Charge any additional fee required.

Signature

Dated: August 1, 2003

Robert M. Barrett
Reg. No. 30,142
BELL, BOYD & LLOYD LLC
P.O. Box 1135
Chicago, IL 60690-1135
Phone: 312-807-4204

I certify that this document and fee is being deposited on 08-1-2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Signature of Person Mailing Correspondence

Robert J. Buccieri

Typed or Printed Name of Person Mailing Correspondence

CC:


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
DI-5373 CON

In Re Application Of:

Naggi et al.



Serial No.

09/882,187

Filing Date

June 15, 2001

Examiner

J. Young

Group Art Unit

1623

Title: PERITONEAL DIALYSIS SOLUTION CONTAINING MODIFIED ICODEXTRINS

RECEIVED

AUG 06 2003

TECH CENTER 1600/2000

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

 the statement specified in 37 CFR 1.97(e);


OR

 the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
 (Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
 DI-5373 CON

In Re Application: Naggi et al.



Serial No.
 09/882,187

Filing Date
 June 15, 2001

Examiner
 J. Young

Group Art Unit
 1623

PERITONEAL DIALYSIS SOLUTION CONTAINING MODIFIED ICODEXTRINS

RECEIVED

AUG 06 2003

TECH CENTER 1600/2900

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- A check in the amount of \$180.00 is attached.
- The Director is hereby authorized to charge and credit Deposit Account No. 02-1818 as described below.
 - Charge the amount of
 - Credit any overpayment.
 - Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (F:

 (Date)

 Signature

 Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on 08-01-2003 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

 Signature of Person Mailing Correspondence

Robert J. Buccieri

 Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

 Signature

Dated: August 1, 2003

Robert M. Barrett

Reg. No. 30,142

BELL, BOYD & LLOYD LLC

P.O. Box 1135

Chicago, IL 60690-1135

Phone: 312-807-4204

CC:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT


(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.

DI-5373 CON

In Re Application Of:

Nagiset al.



Serial No.

09/882,187

Filing Date

June 15, 2001

Examiner

J. Young

Group Art Unit

1623

Title: PERITONEAL DIALYSIS SOLUTION CONTAINING MODIFIED ICODEXTRINS

RECEIVED

AUG 06 2003

~~TECH CENTER 1600/2900~~

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

 the statement specified in 37 CFR 1.97(e);**OR** the fee set forth in 37 CFR 1.17(p).



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Naggi et al.
Appl. No.: 09/882,187
Conf. No.: 8866
Filed: June 15, 2001
Title: PERITONEAL DIALYSIS SOLUTION CONTAINING MODIFIED ICODEXTRINS
Art Unit: 1623
Examiner: J. Young
Docket No.: DI-5373 CON

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 37 C.F.R. 1.97, and 37 C.F.R. 1.98, Applicants request that a citation and examination of the references cited below, and on the attached PTO-1449 form, copies of which are enclosed, be made during the course of examination of the above-identified application for United States patent.

OTHER DOCUMENTS

Mistry et al., *A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis*, Kidney Int., August 1994, 46(2) pp. 496-503.

Peers et al., *Icodextrin: overview of clinical experience*, Perit. Dial. Int., Jan.-Feb. 1997, 17(1) pp. 22-26.

Posthumus et al., *Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance*, Nephrol. Dial. Transplant, Mar. 1997, 12(3) pp. 550-3.

Peers et al., *Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume*, Artif. Organs, January 1998, 22(1) pp. 8-12.

Krediet et al., *Icodextrin's effects on peritoneal transport*, Perit. Dial. Int., Jan.-Feb. 1997, 17(1) pp. 35-41.

Posthumus et al., *Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations*, Nephrol. Dial. Transplant, Sep. 1998, 13(9) pp. 2341-4.

Applicants look forward to early and favorable consideration of this matter.

Respectfully submitted,

BELL, BOYD & LLOYD LLC

BY 

Robert M. Barrett


Reg. No. 30,142

P.O. Box 1135

Chicago, Illinois 60690-1135

Phone: (312) 807-4204

Dated: August 1, 2003



SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)			Atty Docket No. DI-5373 CON	Application No. 09/882,187
PTO Form 1449			Applicant Naggi et al.	
			Filing Date June 15, 2001	Group 1623

RECEIVED
AUG 06 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner's Initials		Document Number	Publication Date	Inventor	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner's Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No

Examiner's Initials	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Mistry et al., <i>A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solutions in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis</i> , Kidney Int., August 1994, 46(2) pp. 496-503.
	Peers et al., <i>Icodextrin: overview of clinical experience</i> , Perit. Dial. Int., Jan.-Feb. 1997, 17(1) pp. 22-26.
	Posthumus et al., <i>Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance</i> , Nephrol. Dial. Transplant, Mar. 1997, 12(3) pp. 550-3.
	Peers et al., <i>Icodextrin provides long dwell peritoneal dialysis and maintenance of intraperitoneal volume</i> , Artif. Organs, January 1998, 22(1) pp. 8-12.
	Krediet et al., <i>Icodextrin's effects on peritoneal transport</i> , Perit. Dial. Int., Jan.-Feb. 1997, 17(1) pp. 35-41.
	Posthumus et al., <i>Icodextrin use in CCPD patients during peritonitis: ultrafiltration and serum disaccharide concentrations</i> , Nephrol. Dial. Transplant, Sep. 1998, 13(9) pp. 2341-4.

Examiner:	Date Considered:
*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	